Influenza

Infectious Disease·MeSH: Influenza, Human

Prevalence

0.1 / 100K

174 drugs in development·36 companies·37 clinical trials

Drug Pipeline by Phase

Approved(20)

Drug	Company
amoxicillin	Aptinyx Inc. (APTX)
amoxicillin	Miromatrix Medical Inc. (MIRO)
amoxicillin	SUNSET ISLAND GROUP (SUN)
banlangen granules	Fuss Brands Corp. (FBDS)
BinaxNOW® / Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)
ceftriaxone	Teva Pharmaceutical Industries Limited (TEVA)
ciprofloxacin	SUNSET ISLAND GROUP (SUN)
ciprofloxacin	AMARIN CORP PLCUK (AMRN)
ciprofloxacin	DR REDDYS LABORATORIES LTD (RDY)
ciprofloxacin	Prestige Consumer Healthcare Inc. (PBH)
ciprofloxacin	ANI PHARMACEUTICALS INC (ANIP)
ciprofloxacin	Altamira Therapeutics Ltd. (CYTOF)
clarithromycin	SUNSET ISLAND GROUP (SUN)
Double - Coptis Suppository	China Health Industries Holdings, Inc. (CHHE)
Double-Coptis Suppository	China Health Industries Holdings, Inc. (CHHE)
ID NOW® rapid molecular system	ABBOTT LABORATORIES (ABT)
Influvac™	ABBOTT LABORATORIES (ABT)
KOSTAIVE (ARCT-154)	Arcturus Therapeutics Holdings Inc. (ARCT)
rapivab	BIOCRYST PHARMACEUTICALS INC (BCRX)
RAPIVAB (peramivir injection)	BIOCRYST PHARMACEUTICALS INC (BCRX)

Phase 3(49)

Drug	Company
Adjuvanted Quadrivalent Influenza Vaccine	Moderna, Inc. (MRNA)
ARCT-2301 (bivalent KOSTAIVE)	Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT-2303 (Monovalent XBB1.5)	Arcturus Therapeutics Holdings Inc. (ARCT)
biological/vaccine	BioNTech SE (BNTX)
CD388	Cidara Therapeutics, Inc. (CDTX)
cycloferon	NYMOX PHARMACEUTICAL CORP (NYMXF)
Egg-based Quadrivalent Influenza Vaccine	Moderna, Inc. (MRNA)
high-dose influenza vaccine (split virion	Sanofi (SNY)
high-dose quadrivalent influenza vaccine	Sanofi (SNY)
high-dose trivalent influenza vaccine (split virion	Sanofi (SNY)
Inactivated Influenza Vaccine	Moderna, Inc. (MRNA)
Influenza and COVID-19 Combination A	BioNTech SE (BNTX)
Influenza and COVID-19 Combination B	BioNTech SE (BNTX)
Influenza Vaccine	Moderna, Inc. (MRNA)
Investigational COVID-19 Vaccine Lot A	Moderna, Inc. (MRNA)
Investigational COVID-19 Vaccine Lot B	Moderna, Inc. (MRNA)
Investigational Influenza Vaccine	Moderna, Inc. (MRNA)
Licensed influenza vaccine	BioNTech SE (BNTX)
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine	Moderna, Inc. (MRNA)
mRNA-1010	Moderna, Inc. (MRNA)
mrna-1018-h5	Moderna, Inc. (MRNA)
mRNA-1045	Moderna, Inc. (MRNA)
mRNA-1083 Composition 1 Dose A Lot A	Moderna, Inc. (MRNA)
mRNA-1083 Composition 1 Dose A Lot B	Moderna, Inc. (MRNA)
mRNA-1083 Composition 1 Dose B	Moderna, Inc. (MRNA)
mRNA-1083 Composition 1 Dose C	Moderna, Inc. (MRNA)
mRNA-1083 Composition 2 Dose A	Moderna, Inc. (MRNA)
mRNA-1083 Composition 2 Dose B	Moderna, Inc. (MRNA)
mRNA-1083 Composition 3 Dose A	Moderna, Inc. (MRNA)
mRNA-1083 Composition 3 Dose B	Moderna, Inc. (MRNA)
Purified inactivated rabies vaccine - Imovax® Rabies	Sanofi (SNY)
Purified inactivated rabies vaccine - Verorab®	Sanofi (SNY)
quadrivalent inactivated influenza vaccine	Sanofi (SNY)
quadrivalent influenza standard dose vaccine	Sanofi (SNY)
quadrivalent influenza vaccine	Sanofi (SNY)
quadrivalent influenza vaccine (split virion	Sanofi (SNY)
recombinant influenza vaccine	Sanofi (SNY)
rsv vaccine 1	Sanofi (SNY)
rsv vaccine formulation 1 dose	Sanofi (SNY)
rsv vaccine formulation 7 dose	Sanofi (SNY)
standard-dose inactivated influenza vaccine quadrivalent	Sanofi (SNY)
standard-dose influenza virus surface antigens	Sanofi (SNY)
standard-dose quadrivalent influenza vaccine	Sanofi (SNY)
standard-dose trivalent influenza vaccine (split virion	Sanofi (SNY)
TEV-48574 Dose Regimen A	Sanofi (SNY)
tiv mrna-ha vaccine 2	Sanofi (SNY)
trivalent influenza vaccine 1 sp shz tiv1	Sanofi (SNY)
trivalent influenza vaccine 2 sp shz tiv2	Sanofi (SNY)
trivalent recombinant influenza vaccine	Sanofi (SNY)

Phase 2(25)

Drug	Company
15 µg h5n1 antigen plus mf59	GH Research PLC (GHRS)
15 µg h5n8 antigen plus half dose as03a	GH Research PLC (GHRS)
15 µg h5n8 antigen plus mf59	GH Research PLC (GHRS)
3.75 µg h5n1 antigen plus mf59	GH Research PLC (GHRS)
3.75 µg h5n8 antigen plus half dose as03a	GH Research PLC (GHRS)
3.75 µg h5n8 antigen plus mf59	GH Research PLC (GHRS)
7.5 µg h5n1 antigen plus mf59	GH Research PLC (GHRS)
7.5 µg h5n8 antigen plus half dose as03a	GH Research PLC (GHRS)
7.5 µg h5n8 antigen plus mf59	GH Research PLC (GHRS)
arct-2304	Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT-810	Arcturus Therapeutics Holdings Inc. (ARCT)
azd4117	ASTRAZENECA PLC (AZN)
azd5315	ASTRAZENECA PLC (AZN)
bIRV	BioNTech SE (BNTX)
CC-42344	Cocrystal Pharma, Inc. (COCP)
covid-19 mrna vaccine	Sanofi (SNY)
influenza a/france/759/2021 virus	TRAWS PHARMA, INC. (ONTX)
nv-387	NANOVIRICIDES, INC. (NNVC)
qIRV	BioNTech SE (BNTX)
QIV	BioNTech SE (BNTX)
sab-176	SAB BIOTHERAPEUTICS, INC. (SABS)
TEV-48574 Dose Regiment B	Sanofi (SNY)
tIRV	BioNTech SE (BNTX)
tivoxavir marboxil	TRAWS PHARMA, INC. (ONTX)
trx-100	TRAWS PHARMA, INC. (ONTX)

Phase 1(38)

Drug	Company
alvr106	Kalaris Therapeutics, Inc. (KLRS)
augment-tasmania influenza vaccine	Sanofi (SNY)
control vaccine older adults	Arcturus Therapeutics Holdings Inc. (ARCT)
control vaccine younger adults	Arcturus Therapeutics Holdings Inc. (ARCT)
COVID-19 Vaccine	BioNTech SE (BNTX)
h3 mrna / lnp vaccine	Sanofi (SNY)
high dose quadrivalent influenza vaccine	Sanofi (SNY)
Influenza A/Texas/71/2017	UNITED THERAPEUTICS Corp (UTHR)
intranasal influenza vaccine	MYMETICS CORP (MYMX)
Investigational COVID-19 Vaccine	BioNTech SE (BNTX)
Investigational Influenza Vaccine	BioNTech SE (BNTX)
Licensed COVID-19 Vaccine	BioNTech SE (BNTX)
Licensed Influenza Vaccine 1	BioNTech SE (BNTX)
Licensed Influenza Vaccine 2	BioNTech SE (BNTX)
Licensed Influenza Vaccine 3	BioNTech SE (BNTX)
LUNAR-FLU (seasonal influenza candidate)	Arcturus Therapeutics Holdings Inc. (ARCT)
LUNAR-H5N1	Arcturus Therapeutics Holdings Inc. (ARCT)
MF59	Valneva SE (VALN)
MF59	Cidara Therapeutics, Inc. (CDTX)
mrna na vaccine	Sanofi (SNY)
quadrivalent recombinant influenza vaccine	Sanofi (SNY)
quadrivalent riv with 2018-2019 nh h3 strain	Sanofi (SNY)
quadrivalent riv with h3 strain 1	Sanofi (SNY)
quadrivalent riv with h3 strain 2	Sanofi (SNY)
quadrivalent riv with h3 strain 3	Sanofi (SNY)
quadrivalent riv with h3 strain 4	Sanofi (SNY)
rsv vaccine 2	Sanofi (SNY)
rsv vaccine formulation 2 dose	Sanofi (SNY)
rsv vaccine formulation 3 dose	Sanofi (SNY)
rsv vaccine formulation 4 dose	Sanofi (SNY)
rsv vaccine formulation 5 dose	Sanofi (SNY)
rsv vaccine formulation 6 dose	Sanofi (SNY)
rsv vaccine formulation 8 dose	Sanofi (SNY)
rsv/hmpv/piv3 vaccine	Sanofi (SNY)
tiv-2x darwin influenza vaccine	Sanofi (SNY)
trivalent-darwin influenza vaccine	Sanofi (SNY)
trivalent-tasmania influenza vaccine	Sanofi (SNY)
VRC-FLUMOS0116-00-VP	Cidara Therapeutics, Inc. (CDTX)

Preclinical(7)

Drug	Company
anqlar	Virpax Pharmaceuticals, Inc. (VRPX)
anti-infective antibody cocktail	XBiotech Inc. (XBIT)
co-dx pcr flu a/b	Co-Diagnostics Inc. (CODX)
combination covid-19	Lucira Health, Inc. (LHDX)
influenza antibody cocktail	XBiotech Inc. (XBIT)
influenza therapeutic	XBiotech Inc. (XBIT)
pds0202	PDS Biotechnology Corp (PDSB)

Unknown(6)

Drug	Company
Alinity® m and m2000™	ABBOTT LABORATORIES (ABT)
BinaxNOW® and Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)
Bivalent ARCT-2301	Arcturus Therapeutics Holdings Inc. (ARCT)
efluelda pre-filled syringe	Sanofi (SNYNF)
efluelda pre-filled syringe	Sanofi (SNY)
Efluelda® Pre-filled syringe	Sanofi (SNY)

Phase 1/Phase 2(16)

Drug	Company
commercial influenza vaccine	SQZ Biotechnologies Co (SQZB)
mRNA-1018 for H5 Only	Moderna, Inc. (MRNA)
mRNA-1018 for H5 Only-CG	Moderna, Inc. (MRNA)
mRNA-1018 for H5N8	Moderna, Inc. (MRNA)
mRNA-1018 for H7 Only	Moderna, Inc. (MRNA)
mRNA-1018 for H7N9	Moderna, Inc. (MRNA)
pandemic flu h5 ha mrna sd2 vaccine	Sanofi (SNY)
pandemic flu h5 mrna vaccine	Sanofi (SNY)
quadrivalent influenza high-dose vaccine	Sanofi (SNY)
quadrivalent influenza mrna vaccine mrt5421	Sanofi (SNY)
quadrivalent influenza mrna vaccine mrt5424	Sanofi (SNY)
quadrivalent influenza mrna vaccine mrt5429	Sanofi (SNY)
recombinant influenza vaccine candidate	SQZ Biotechnologies Co (SQZB)
tiv mrna-neuraminidase	Sanofi (SNY)
tiv mrna-neuraminidase	Sanofi (SNY)
trivalent messenger ribonucleic acid hemagglutinin vaccine 1	Sanofi (SNY)

Phase 2/Phase 3(6)

Drug	Company
15 µg h5n1 antigen plus full dose as03a	GH Research PLC (GHRS)
15 µg h5n8 antigen plus full dose as03a	GH Research PLC (GHRS)
3.75 µg h5n1 antigen plus full dose as03a	GH Research PLC (GHRS)
3.75 µg h5n8 antigen plus full dose as03a	GH Research PLC (GHRS)
7.5 µg h5n1 antigen plus full dose as03a	GH Research PLC (GHRS)
7.5 µg h5n8 antigen plus full dose as03a	GH Research PLC (GHRS)

Phase 4(7)

Drug	Company
COVID-19 Vaccine	Moderna, Inc. (MRNA)
Flumist Quadrivalent Nasal Product	Cidara Therapeutics, Inc. (CDTX)
fluzone high-dose quadrivalent vaccine	Sanofi (SNY)
fluzone high-dose vaccine	Sanofi (SNY)
fluzone quadrivalent vaccine	Sanofi (SNY)
Influenza Fluzone vaccine	Cidara Therapeutics, Inc. (CDTX)
mRNA-1345	Moderna, Inc. (MRNA)

Compare drugs

amoxicillin vs banlangen granules amoxicillin vs BinaxNOW® / Panbio® rapid testing platforms amoxicillin vs ceftriaxone

Frequently asked questions

How many drugs are in development for Influenza?

BioSniper tracks 174 drugs in development for Influenza across 36 companies.

How many clinical trials target Influenza?

There are 37 clinical trials targeting Influenza tracked by BioSniper.

What is the prevalence of Influenza?

The estimated prevalence of Influenza is approximately 0.1 per 100,000 population.

Deep-dive into Influenza

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis